Clinical Trials Logo

Measles clinical trials

View clinical trials related to Measles.

Filter by:

NCT ID: NCT01188343 Completed - Measles Clinical Trials

Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers

Start date: August 2010
Phase: Phase 3
Study type: Interventional

This study is designed to compare the immunogenicity of Japanese encephalitis chimeric virus vaccine (JE-CV) and measles-mumps-rubella (MMR)vaccine when given together or when given at separate visits 6 weeks apart in toddlers aged 12 to 18 months. Primary objective: - To demonstrate the non-inferiority of the antibody responses in terms of seroconversion of the concomitant administration of JE-CV and MMR compared to the antibody responses after the single administration of JE-CV and MMR vaccine. Secondary objectives: - To describe the immune response to JE CV and MMR before and after one dose of JE CV and MMR vaccine, respectively. - To describe the safety of a single dose of JE-CV and MMR vaccine (given separately at a 6-week interval and the safety of the concomitant administration of JE-CV and MMR vaccine in all subjects up to 6 months after last vaccination.

NCT ID: NCT00986232 Completed - Measles Clinical Trials

ProQuad Dose Selection Study (V221-011)(COMPLETED)

Start date: April 1999
Phase: Phase 2
Study type: Interventional

A Study comparing three different doses of ProQuad to concomitant administration of M-M-R II and PUVV (Process Upgrade Varicella Vaccine) vaccines.

NCT ID: NCT00985166 Completed - Measles Clinical Trials

A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)

Start date: August 2000
Phase: Phase 3
Study type: Interventional

The study was conducted to determine if ProQuad may be used in place of the second dose of M-M-R II routinely given to children 4 to 6 years old who were previously immunized with M-M-R II and Varivax.

NCT ID: NCT00985153 Completed - Measles Clinical Trials

Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)

Start date: March 2000
Phase: Phase 3
Study type: Interventional

This study will compare three consistency lots of ProQuad to each other as well as to M-M-R II and Varivax, administered concomitantly at different injection sites, with respect to immunogenicity, safety, and tolerability.

NCT ID: NCT00984295 Completed - Measles Clinical Trials

Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines

Start date: June 2000
Phase: Phase 3
Study type: Interventional

This study will assess the safety and immunogenicity of ProQuad when administered concomitantly and nonconcomitantly with Tripedia and Comvax.

NCT ID: NCT00975507 Completed - Measles Clinical Trials

ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)

Start date: March 1998
Phase: Phase 3
Study type: Interventional

This study will compare Measles, Mumps, Rubella, and Varicella Vaccine (V221) and concomitant administration of Varivax and M-M-R II vaccines in healthy children.

NCT ID: NCT00969436 Completed - Measles Clinical Trials

Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM

Start date: November 9, 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess non-inferiority of two different vaccination regimens using GSK Biological's MMRV vaccine (two doses at 9 and 15 months) or Priorix™ (9 months) and one dose of MMRV vaccine (15 months) to the current standard of care which is Priorix™ administered at 9 months of age followed by concomitant administration of Priorix™ with Varilrix™ at 15 months of age in a measles endemic environment such as India.

NCT ID: NCT00962819 Completed - Measles Clinical Trials

Measles, Mumps, and Rubella (MMR) Immunity in College Students

Start date: March 2010
Phase:
Study type: Observational

This study will lay the foundation for determining the underlying reasons for lack of immunity to mumps that led to the 2006 mumps outbreak on college campuses in the Mid West, and it will assess the potential for similar outbreaks of measles and rubella. A total of 70 to 80 college students (age 18 to 22) on the Emory campus (or nearby college campuses or the community) will be assessed for antibodies to measles, mumps or rubella by drawing a one-time blood sample. Their medical records will be verified for documentation of immunization with MMR vaccine prior to enrollment in the study. If a study volunteer is found to not have MMR immunity, they will be offered an MMR-II vaccine. For this group, additional blood specimens will be obtained.

NCT ID: NCT00892775 Completed - Measles Clinical Trials

Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds

Start date: June 3, 2009
Phase: Phase 2
Study type: Interventional

This study is undertaken to generate clinical data on GSK Biologicals' combined measles-mumps-rubella-varicella vaccine manufactured with measles and rubella obtained from newly established working seed viruses which are one passage further than the current working seed viruses. The measles-mumps-rubella-varicella vaccine manufactured with the current working seed viruses will serve as comparator. A seed lot system is a system according to which successive batches of a vaccine are derived from the same master seed virus. For routine production, a working seed lot is prepared from the master seed virus.

NCT ID: NCT00891007 Completed - Measles Clinical Trials

Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years

Start date: June 2009
Phase: Phase 2
Study type: Interventional

Partially randomized, controlled Phase II study to evaluate safety, immunogenicity and dose response of the measles vaccine MVA mBN85B in healthy children aged 6 months to 6 years.